Jacek Kwiatkowski

Jacek Kwiatkowski

Auto-generated profile, based on publicly available information

Jacek Kwiatkowski

Department of Architecture, Institute of Civil Engineering, Faculty of Civil and Environmental Engineering, Warsaw University of Life Sciences, Poland

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Journal of Clinical Virology
Verified
Journal Article
Closed access
MBMonika Biernat
Monika Biernat
AZAleksander Zińczuk
Aleksander Zińczuk
PBPaweł Biernat
Paweł Biernat
ABAleksandra Bogucka-Fedorczuk
Aleksandra Bogucka-Fedorczuk
JKJacek Kwiatkowski
Jacek Kwiatkowski
TWTomasz Wrobel
Tomasz Wrobel

8 March 2021 in Viruses
Verified
Journal Article
Open access
PDF file
MBMonika Biernat
Monika Biernat
AKAnna Kolasińska
Anna Kolasińska
JKJacek Kwiatkowski
Jacek Kwiatkowski
DUDonata Urbaniak-Kujda
Donata Urbaniak-Kujda
PBPaweł Biernat
Paweł Biernat
TWTomasz Wrobel
Tomasz Wrobel
The use of convalescent plasma in the treatment of COVID-19 may lead to a milder course of infection and has been associated with improved outcomes. Determining optimal treatments in high risk populations is crucial, as is the case in those with hematological malignancies. We analyzed a cohort of 23 patients with hematological malignancies and COVID-19 who had received plasma 48–72 h after the diagnosis of infection and compared it with a historical group of 22 patients who received other therapy. Overall survival in those who received convalescent plasma was significantly higher than in the historical group (p = 0.03460). The plasma–treated group also showed a significantly milder course of infection (p = 0.03807), characterized by less severe symptoms and faster recovery (p = 0.00001). In conclusion, we have demonstrated that convalescent plasma is an effective treatment and its early administration leads to clinical improvement, increased viral clearance and longer overall survival in patients with hematological malignancies and COVID-19. To our knowledge, this is the first report to analyze the efficacy of convalescent plasma in a cohort of patients with hematological malignancies.

19 May 2015 in Platelets
Verified
Journal Article
Closed access
RMRafał Małecki
Rafał Małecki
MGMałgorzata Gacka
Małgorzata Gacka
MKMałgorzata Kuliszkiewicz-Janus
Małgorzata Kuliszkiewicz-Janus
UJUrszula Jakobsche-Policht
Urszula Jakobsche-Policht
JKJacek Kwiatkowski
Jacek Kwiatkowski
AUAnetta Undas
Anetta Undas
Patients with increased thromboembolic risk tend to form denser fibrin clots which are relatively resistant to lysis. We sought to investigate whether essential thrombocythemia (ET) is associated with altered fibrin clot properties in plasma. Ex vivo plasma fibrin clot permeability coefficient (Ks), turbidimetry and clot lysis time (CLT) were measured in 43 consecutive patients with ET (platelet count from 245 to 991 × 10(3)/µL) and 50 control subjects matched for age, sex and comorbidities. Fibrinolysis proteins and inhibitors together with platelet activation markers were determined. Reduced Ks (-38%, p < 0.0001) and prolonged CLT (+34%, p < 0.0001) were observed in ET. The differences remained significant after adjustment for fibrinogen and platelet count. ET was associated with a slightly shorter lag phase (-5%, p = 0.01) and higher maximum absorbency of the turbidimetric curve (+6%, p < 0.001). The ET patients had higher plasma P-selectin by 193% (p < 0.00001) and platelet factor 4 (PF4) by 173% (p < 0.00001), with higher P-selectin observed in 19 (44%) patients with JAK-2 gene V617F mutation. Higher t-PA (+20%, p < 0.001), 23% higher plasminogen activator inhibitor-1, PAI-1 (+23%, p < 0.01) and unaltered thrombin-activatable fibrinolysis inhibitor, plasminogen and α2-antiplasmin activity were found in the ET group. Ks inversely correlated with fibrinogen, PF4 and C-reactive protein. CLT positively correlated only with PAI-1. Patients with ET display prothrombotic plasma fibrin clot phenotype including impaired fibrinolysis, which represents a new prothrombotic mechanism in this disease.

10 March 2021 in Pharmacology
Verified
Journal Article
Closed access
PDF file
JKJacek Kwiatkowski
Jacek Kwiatkowski
MKMałgorzata Kuliszkiewicz-Janus
Małgorzata Kuliszkiewicz-Janus
WRWeronika Rymer
Weronika Rymer
BJBożena Jaźwiec
Bożena Jaźwiec
RMRafał Małecki
Rafał Małecki
Background and Purpose: When choosing a cytoreduction method for patients suffering from essential thrombocythemia (ET), it is important to know the safety profile of the medicine used. Few articles have been published about the effects of hydroxycarbamide (hydroxyurea, HU) and anagrelide (ANA) on renal function in ET patients. This study is the largest analysis of nephrotoxicity of cytoreductive drugs used in ET therapy so far, which additionally includes risk factors for the progression of kidney disease and coexisting genetic mutation. Experimental Approach: The retrospective study included 310 patients diagnosed with ET. Demographic data, comorbidities, Cr, and estimated glomerular filtration rate (eGFR) were all taken into account prior to diagnosis and after 6 months of HU and ANA treatment. Key Results: A statistically significant difference was found between Cr and eGFR levels at baseline and after 6 months of treatment (p < 0.001). The applied treatment (HU and ANA) had the greatest impact on kidney function. ANA significantly increased the risk of worsening renal function in contrary to hydroxycarbamide after 6 months of treatment (eGFR change: median +1 mL/min/1.73 m2 [interquartile range (IQR) (−4)–(+7)] in the HU group vss. median −13 mL/min/1.73 m2 [IQR (−18)–(−6)] in the ANA group, odds ratio [OR] 7.92 95% confidence interval [95% CI] [4.17–15.08], p < 0.001). Lowering of eGFR 50% decrease in eGFR was observed. The chance for an increase in Cr levels was higher in people with pre-existing arterial hypertension (OR 1.92 CI = 95% [1.21–3.05], p = 0.006). Sex, type of mutation found (JAK2 V617F or CALR), and previous renal impairment did not affect renal function after 6 months of treatment. In addition, there was no difference in the efficacy of ET treatment between HU and ANA (p = 0.998). Conclusions and Implications: The observations indicate that ANA should be used in patients with ET with great caution and taking into account the risk of worsened kidney function.

1 February 2018 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
ELEdyta Lelonek
Edyta Lelonek
ŁMŁukasz Matusiak
Łukasz Matusiak
TWTomasz Wrobel
Tomasz Wrobel
JKJacek Kwiatkowski
Jacek Kwiatkowski
Jacek C. SzepietowskiJacek C. Szepietowski
Jacek C. Szepietowski
Aquagenic pruritus (AP) has a significant influence on quality of life (QoL) in patients with polycy...

26 April 2019 in Hematological Oncology
Verified
Journal Article
Closed access
PDF file
JDJoanna Drozd-Sokołowska
Joanna Drozd-Sokołowska
Jan ZauchaJan Zaucha
Jan Zaucha
TŻTomasz Żółtak
Tomasz Żółtak
KJKrzysztof Jamroziak
Krzysztof Jamroziak
OGOlga Grzybowska‐Izydorczyk
Olga Grzybowska‐Izydorczyk
WWWiesław Wiktor‐Jędrzejczak
Wiesław Wiktor‐Jędrzejczak